Uric Acid Level Reference Tool

About Uric Acid

Uric acid is the end product of purine metabolism in humans. Purines come from both endogenous breakdown of cells and from dietary sources, particularly animal proteins. In most other mammals, uric acid is broken down further by the enzyme uricase; humans lost functional uricase during primate evolution, and research suggests as a result humans carry uric acid levels several times higher than other animals. Roughly two-thirds of urate is excreted by the kidneys and the remainder by the gut.

Consensus thresholds typically suggest that when serum urate exceeds the saturation point for monosodium urate — approximately 6.8 mg/dL (405 µmol/L) — crystals may deposit in joints and soft tissues. Research suggests these crystals are linked to gout, an inflammatory arthritis. Above-typical urate has also been studied as a potential cardiovascular and renal risk marker, although causality remains debated.

Reference Ranges by Sex

Multiply mg/dL by 59.48 to convert to µmol/L. Cutoffs reflect commonly cited reference ranges; laboratories may use slightly different values.

Above-Typical Uric Acid and Gout

It is worth being precise about language in educational discussion. Hyperuricemia is the term clinicians may use for serum uric acid above the typical reference range. Gout is a clinical condition associated with joint inflammation linked to monosodium urate crystal deposition — most classically the first metatarsophalangeal joint (the big toe), but any joint can be affected. Research suggests many people have above-typical uric acid for years or decades without ever developing gout. Urate may also transiently drop during an acute flare. Only a qualified healthcare provider can diagnose gout or assess flare risk in an individual.

For people whose gout has been diagnosed and managed by a clinician, the ACR 2020 Guideline for the Management of Gout (FitzGerald JD et al., Arthritis & Rheumatology 2020) typically discusses urate-lowering therapy targets of below 6 mg/dL (360 µmol/L), or below 5 mg/dL (300 µmol/L) in those with tophi or frequent flares. Consensus thresholds typically suggest that for above-typical uric acid without symptoms, pharmacologic lowering is not routinely recommended. Decisions are made in conjunction with a healthcare provider.

Dietary Factors

Research suggests several dietary factors may be associated with higher serum urate:

• Organ meats (liver, kidney, sweetbreads) — very high purine content.
• Certain seafood — anchovies, sardines, mackerel, herring, mussels.
• Alcohol, especially beer — research suggests beer combines ethanol (associated with reduced urinary urate excretion) with purines from yeast; spirits to a lesser extent; wine modestly.
• Fructose, particularly high-fructose corn syrup — found in many sugar-sweetened soft drinks and processed foods; research suggests it may accelerate urate production via ATP depletion in the liver.
• Red meat and game — a moderate but consistent association in observational studies.

Conversely, several dietary factors have been associated with lower urate in research: dairy (particularly low-fat), coffee, cherries, and vitamin C. A Mediterranean or DASH-style dietary pattern is often discussed positively in this context. Research suggests dietary change may lower serum urate by about 1 mg/dL on average — helpful for general wellness, though individual responses vary. Dietary decisions should be discussed with a qualified healthcare provider or registered dietitian.

Medications That May Raise Uric Acid

Research suggests above-typical uric acid in older adults may be associated with medication use. Commonly cited contributors include:

• Thiazide and loop diuretics (hydrochlorothiazide, furosemide) — associated with reduced urinary urate excretion.
• Low-dose aspirin (below about 2 g/day) — associated with reduced urate excretion; cardiovascular considerations are typically weighed by the prescribing clinician.
• Cyclosporine and tacrolimus — used post-transplant.
• Pyrazinamide and ethambutol — anti-tuberculosis drugs.
• Niacin at pharmacologic doses — used for lipid management.

On the other side, research suggests several commonly prescribed drugs may be associated with lower uric acid:

• Losartan (and, less consistently, some other ARBs) — associated with a mild uricosuric effect.
• Fenofibrate — lipid-lowering with mild urate reduction reported.
• SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin) — research suggests they may lower serum uric acid by ~0.5–1 mg/dL via increased urinary excretion; observational data have suggested an association with reduced gout flare incidence in type 2 diabetes.

Any medication-related decisions should be made together with the prescribing clinician.

Kidney Function and Uric Acid

Because the kidneys excrete about two-thirds of uric acid, research suggests chronic kidney disease (CKD) may be associated with above-typical uric acid. As eGFR falls, the kidneys may retain more urate. Conversely, above-typical uric acid has been associated with faster CKD progression in observational data, though trials of urate lowering for renal protection have produced mixed results. A healthcare provider can advise on whether kidney function testing (creatinine, eGFR) is appropriate alongside a uric acid trend.

Therapy Categories Discussed in ACR 2020 (Educational)

For people whose gout has been diagnosed and managed by a clinician, the ACR 2020 guideline discusses several urate-lowering therapy categories. This is educational background only — any therapy decisions are made between an individual and their healthcare provider.

• Allopurinol — a xanthine oxidase inhibitor often discussed as a first-line option. Dosing typically starts low (often 100 mg/day or lower in CKD) and is titrated. HLA-B*5801 screening is sometimes considered in people of Southeast Asian or Black descent given the rare but serious hypersensitivity syndrome described in research.
• Febuxostat — an alternative xanthine oxidase inhibitor sometimes discussed for people who do not tolerate allopurinol. Research (the CARES and FAST trials) has produced different cardiovascular signals; risk/benefit is individualised by the clinician.
• Probenecid — a uricosuric agent, less commonly used in CKD.
• Pegloticase — an IV recombinant uricase discussed for refractory cases.